News

National Institute for Health and Care Excellence1d
Published guidance, NICE advice and quality standards
Guidance programme Guidance programme Antimicrobial prescribing guidelines (20) Cancer service guidelines (8) Clinical guidelines (226) COVID-19 rapid guidelines (3) Diagnostics guidance (50) Health ...
The National Institute for Health and Care Excellence4d
Harnessing digital innovation for children's mental health
In this guest blog, Dale Greenwood, mental health lead for East London NHS Foundation Trust, shares how his trust implemented ...
The National Institute for Health and Care Excellence9d
Final draft guidance finds benefits of 2 Alzheimer’s treatments remain too small to justify the additional costs to the NHS
The benefits of Alzheimer’s treatments donanemab and lecanemab remain too small to justify the additional costs ...
The National Institute for Health and Care Excellence12d
‘Artificial pancreas’ transforming the lives of thousands of children and young people with type 1 diabetes
More than 30,000 children and young people are living with type 1 diabetes in England. Usual management involves finger prick testing and injecting insulin multiple times a day. HCL systems remove the ...
National Institute for Health and Care Excellence16d
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212] - NICE
NICE Guidance; Conditions and diseases; Blood and immune system conditions; Blood and bone marrow cancers; Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory ...
National Institute for Health and Care Excellence18d
Updated guideline to increase access to treatments for early-stage chronic heart failure could reduce deaths and hospital admissions by thousands | NICE
The draft guideline recommends medicines be given up to a year earlier - helping people live well for longer. We’re updating the recommendations for drug treatments in our clinical guideline on the ...
National Institute for Health and Care Excellence24d
Linzagolix for treating symptoms of endometriosis - NICE
Evidence-based recommendation on linzagolix (Yselty) for treating symptoms of endometriosis in adults of reproductive age.. Last reviewed: 04 June 2025 Next review: This guidance will be reviewed if ...
National Institute for Health and Care Excellence25d
Project information | Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177] | Guidance | NICE
Date Update 03 June 2025 - 24 June 2025 Draft guidance: 1 : 13 May 2025 ...
National Institute for Health and Care Excellence15d
NICE leads the way in approving breakthrough treatment for multiple myeloma
NICE leads the way in approving breakthrough treatment for multiple myeloma . People in England will become the first in the world to receive belantamab mafodotin for this indication following our ...
National Institute for Health and Care Excellence25d
Fostering the digital health tech revolution - NICE
Programme director for Healthtech strategy and development. Imagine a future where groundbreaking health technologies reach NHS patients in a matter of months rather than years. Where innovative ...
National Institute for Health and Care Excellence29d
Learn more about our updated maternal and child nutrition guideline
We're joined by 2 members of the guideline committee, health visitor Karen McLean and health psychologist Vivien Swanson, to discuss updates to our guideline supporting nutrition and weight management ...
National Institute for Health and Care Excellence16d
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212] - NICE
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212] ...